Lumida
/AMLX
⌘K
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

AMLX
$17.75USD+4.29%+0.73 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$17 – $18

52W RANGE

$7
$19

AI Summary

Stalk
StalkMedium

AMLX remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows above rising EMAs, supporting a medium-term bullish bias. However, overbought conditions and a recent pullback into the 9- and 21-EMA zone advise patience. Execution should be deferred, stalking for acceptance and shallow pullbacks into the rising EMAs to participate in the ongoing trend.

  • Targets 160,000 US PBH patients addressing major unmet medical need
  • Phase III Lucidity trial completes in Q3 2026, paving FDA NDA submission
  • Q1 2026 EPS loss $0.37 misses consensus $0.33 target
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRIC
TREND